


PHARMACEUTICAL 2018



Matinas BioPharma Holdings Inc. Rank 224 of 342





PHARMACEUTICAL 2018



Matinas BioPharma Holdings Inc. Rank 224 of 342

The relative strengths and weaknesses of Matinas BioPharma Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Matinas BioPharma Holdings Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 43% points. The greatest weakness of Matinas BioPharma Holdings Inc. is the variable Net Income, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is 32%, being 14% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	7,964
Cost of Goods Sold	0
Intangible Assets	1,336
Liabilities, Current	2,225
Liabilities, Non-Current	0
Other Assets	3,553
Other Compr. Net Income	0
Other Expenses	-357
Other Liabilities	1,517
Other Net Income	659
Other Revenues	150
Property and Equipment	1,570
Research and Development	9,010
Selling, General and Administrative Expense	7,642

Output Variable	Value in 1000 USD
Assets	14,424
Liabilities	3,742
Expenses	16,295
Revenues	150
Stockholders Equity	10,682
Net Income	-15,486
Comprehensive Net Income	-15,486
Economic Capital Ratio	32%

